Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy
Tewodros Shibabaw Department of Biochemistry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, EthiopiaCorrespondence: Tewodros ShibabawDepartment of Biochemistry, School of Medicine, University of Gondar, P.O. Box 196, Gondar, EthiopiaTel +251910162171Email...
Guardado en:
Autor principal: | Shibabaw T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/55001c93c91743d5a504a9750685497b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A
por: Liu L, et al.
Publicado: (2016) -
Pro-Tumor and Anti-Tumor Functions of IL-17 and of TH17 Cells in Tumor Microenvironment
por: Gulubova M., et al.
Publicado: (2016) -
Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19
por: Zou Y, et al.
Publicado: (2021) -
IL-33/ST2 Axis Deficiency Exacerbates Hepatic Pathology by Regulating Treg and Th17 Cells in Murine Schistosomiasis Japonica
por: Bai Y, et al.
Publicado: (2021) -
Urinary excretion of IL-1β, IL-6 and IL-8 cytokines during relapse and remission of idiopathic nephrotic syndrome
por: Al-Eisa AA, et al.
Publicado: (2017)